What is the Difference Between Menactra and Menveo?

Menactra and Menveo are both meningococcal vaccines used for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. They are conjugate vaccines, meaning they are effective against multiple serotypes of the bacteria. Both vaccines are approved by the FDA for different age groups, and they work by exposing people to a small dose of bacteria or its protein.

The key difference between Menactra and Menveo is the age groups they are approved for:

• Menactra is indicated for active immunization in patients aged 9 months through 55 years.
• Menveo is approved for use in children as young as 2 months of age.

Both Menactra and Menveo are interchangeable for individuals aged 9 months and older, and Menveo, Menactra, and MenQuadfi are interchangeable for individuals aged 2 years and older. This means that if the specific vaccine given to an individual is unable to be determined, they might need to be revaccinated.

Comparative Table: Menactra vs Menveo

Menactra and Menveo are both meningococcal vaccines used for the prevention of infection by Neisseria meningitidis. Here is a table highlighting the differences between the two vaccines:

Both Menactra and Menveo are conjugate vaccines, which means they are effective against specific serotypes of Neisseria meningitidis. The main difference between the two vaccines is the age range for which they are approved. Menactra is not approved for children under 2 years old, while Menveo is approved for children as young as 2 months old. Additionally, Menveo is effective against serotype A, whereas Menactra is not.